← Back to Clinical Trials
Recruiting NCT03943316

NCT03943316 Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03943316
Status Recruiting
Phase
Sponsor New Mexico Cancer Research Alliance
Condition Ovarian Cancer
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2015-12-02
Primary Completion 2025-12-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2015-12-02 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.

Eligibility Criteria

Inclusion Criteria: * All female participants, regardless of ethnicity, who are undergoing cytoreductive surgery for ovarian cancer are eligible for this study * All participants will be eighteen years old or older * Patients must be suspected of having a pathological diagnosis or clinical suspicion of ovarian cancer and be scheduled for surgery for tumor resection. * Ability to understand and the willingness to sign a written informed consent document. * Pathologic confirmation of a diagnosis of epithelial adenocarcinoma of the ovary, fallopian tube, or primary peritoneal cancer (serous, mucinous, clear cell, endometrioid, undifferentiated, mixed, transitional cell) * Women of childbearing potential must have a negative qualitative serum pregnancy test ≤ 2 weeks prior to study entry. * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). Exclusion Criteria: * We do not intend to include participants if they are unable to provide informed consent for this study themselves (e.g. mentally ill patients who require health care proxies to consent for any medical intervention), or vulnerable populations such as prisoners. * Minors under age eighteen. * Pregnant women. * Final pathologic diagnosis that does not confirm invasive epithelial ovarian, tubal, or primary peritoneal cancer

Contact & Investigator

Central Contact

Sarah Adams, MD

✉ SAdams@salud.unm.edu

📞 (505) 925-0461

Principal Investigator

Sarah Adams, MD

PRINCIPAL INVESTIGATOR

UNM Comprehensive Cancer Center

Frequently Asked Questions

Who can join the NCT03943316 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03943316 currently recruiting?

Yes, NCT03943316 is actively recruiting participants. Contact the research team at SAdams@salud.unm.edu for enrollment information.

Where is the NCT03943316 trial being conducted?

This trial is being conducted at Albuquerque, United States.

Who is sponsoring the NCT03943316 clinical trial?

NCT03943316 is sponsored by New Mexico Cancer Research Alliance. The principal investigator is Sarah Adams, MD at UNM Comprehensive Cancer Center. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology